{"id":"W3128342266","doi":"10.1016/j.jtho.2021.01.1605","title":"A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Janssen Biotech; Foundation Medicine; Chugai Pharmaceutical; Genentech; Clinical Excellence Commission; Lunit; Relay Therapeutics; Northwell Health; Apollomics; Pfizer; Incyte; Siemens Medical Solutions USA; AstraZeneca; Novocure; Commission for Environmental Cooperation; MedStar Health Research Institute; Regeneron Pharmaceuticals; Array BioPharma; Agios Pharmaceuticals; Roche; Novartis; Heron Therapeutics; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Medtronic; Ariad Pharmaceuticals; Siemens Healthineers; Amgen; Boehringer Ingelheim; Exelixis; American Lung Association","keywords":"Medicine; Lung cancer; Cancer; Internal medicine; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001865355,0.0001514052,0.0007955547,0.0002286682,0.00003215247,0.000008417671,0.00005942784,0.00006267406,0.0001095855],"category_scores_gemma":[0.00005187144,0.00009033859,0.00006021854,0.0004474473,0.0000390159,0.0001212603,0.00001784035,0.0002306029,4.308056e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005960825,"about_ca_system_score_gemma":0.001328623,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001796222,"about_ca_topic_score_gemma":0.0006416413,"domain_scores_codex":[0.9984861,0.0002208377,0.0006091003,0.0001701808,0.0003283299,0.000185474],"domain_scores_gemma":[0.9981677,0.00007167096,0.0007075978,0.0001721814,0.0007449794,0.0001358942],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01810275,0.02967161,0.8567294,0.0002468567,0.003221056,0.001694649,0.01087099,0.0001435225,0.000586988,0.000002098188,0.0003757691,0.07835428],"study_design_scores_gemma":[0.1817047,0.2158792,0.5552194,0.003583359,0.01787326,0.000813554,0.01531348,0.0001299494,0.007224135,0.00001222048,0.001769627,0.000477044],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978598,0.0006315421,0.000023417,0.0002519661,0.0001334303,0.000817827,0.00002139393,0.000005694935,0.0002549822],"genre_scores_gemma":[0.9974015,0.00002923868,0.002085272,0.00009401552,0.00009638609,0.00005470759,0.00001618133,0.00002084907,0.0002018004],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.30151,"threshold_uncertainty_score":0.3683901,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01810293350768457,"score_gpt":0.4496206825810844,"score_spread":0.4315177490733998,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}